Back to All Combinations
KRAS G13D + TP53
PrognosisGenes Involved
KRAS
TP53
Treatment Implications
Standard chemotherapy + Bevacizumab. Anti-EGFR not indicated. If HER2 co-amplified, consider Trastuzumab Deruxtecan (DESTINY-CRC02 showed efficacy in RAS mutant). TP53 mutations do not currently guide therapy selection.
Recommended Treatments
FOLFOX/FOLFIRI + Bevacizumab
FOLFOXIRI + Bevacizumab
TAS-102 + Bevacizumab
Clinical trials
Treatments to Avoid
Anti-EGFR monoclonal antibodies
Study References
Various retrospective analyses
Key Statistics
5.00%
Prevalence in CRC
No
Targetable
Clinical Notes
Co-occurrence of KRAS G13D and TP53 mutation seen in ~5% of mCRC. TP53 dysfunction may reduce chemotherapy sensitivity but is not therapeutically actionable. Focus on KRAS-driven treatment selection. Test for HER2 amplification as potential targetable co-alteration.
Information
Category: RAS Pathway
Evidence Level: Level 3
Last Updated: Dec 21, 2025
Medical Disclaimer: This information is for educational purposes only and should not replace professional medical advice. Always consult with your oncologist for personalized treatment decisions based on your specific situation.